Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dioxane SCHEMBL10324821 | 1.00 | CA2 (0.35) | CA2TTRTDP1 | |
| Dioxane SCHEMBL8149387 | 1.00 | CA2 (0.35) | CA2TTRTDP1 | |
| Dioxane SCHEMBL2949971 | 0.91 | TTR (0.43) | TTRTDP1 | |
| SCHEMBL4625372 | 0.91 | TTR (0.43) | TTRTDP1 | |
| Tetrahydrofuran SCHEMBL28609324 | 0.89 | ALDH1A1 (0.42) | CA2TDP1 | |
| SCHEMBL28902249 | 0.89 | CA2 (0.33) | CA2 | |
| Tetrahydrofuran SCHEMBL2336993 | 0.89 | ALDH1A1 (0.42) | CA2TDP1 | |
| Tetrahydrofuran SCHEMBL310535 | 0.89 | ALDH1A1 (0.42) | CA2TDP1 | |
| SCHEMBL8859291 | 0.87 | ALDH1A1 (0.40) | CA2TDP1 | |
| SCHEMBL11713823 | 0.87 | ALDH1A1 (0.40) | CA2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599462-B1 | Process of preparing imatinib | CIPLA LTD (IN) | 2013-03-27 | — | — | EP | claimed |
| US-7638627-B2 | Imatinib hydrochloride; reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidineamine with 4-(4-methyl-piperazinomethyl)benzoyl chloride; improved reduction step to simplify, increase yield, improve purity | CIPLA LIMITED (IN) | 2009-12-29 | — | — | US | claimed |
| EP-1905761-A1 | An improved process for the preparation of 4-[2-(methyl-2-pyridinylamino) ethoxy] benzaldehyde, an intermediate for the preparation of rosiglitazone | Cadila Pharmaceuticals Limited (IN) | 2008-04-02 | — | — | EP | claimed |
| US-20060173182-A1 | Process of preparing imatinib and imatinib prepared thereby | CIPLA LIMITED (IN) | 2006-08-03 | — | — | US | claimed |
| EP-1599462-A2 | PROCESS OF PREPARING IMATINIB | Cipla Ltd. (IN) | 2005-11-30 | — | — | EP | claimed |
| WO-2004074502-A2 | A PROCESS OF PREPARING IMATINIB | CIPLA LTD (IN) | 2004-09-02 | — | — | WO | claimed |
| EP-1599462-B1 | Process of preparing imatinib | CIPLA LTD (IN) | 2013-03-27 | — | — | EP | disclosed |
| US-20100179323-A1 | PROCESS FOR MAKING DIPHOSPINE-RUTHENIUM-DIAMINE COMPLEXES | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-07-15 | — | — | US | disclosed |
| EP-1902061-B1 | PROCESS FOR MAKING DIPHOSPHINE-RUTHENIUM-DIAMINE COMPLEXES | REDDY S LAB EU LTD DR (GB) | 2009-12-30 | — | — | EP | disclosed |
| US-7638627-B2 | Imatinib hydrochloride; reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidineamine with 4-(4-methyl-piperazinomethyl)benzoyl chloride; improved reduction step to simplify, increase yield, improve purity | CIPLA LIMITED (IN) | 2009-12-29 | — | — | US | disclosed |
| EP-1905761-A1 | An improved process for the preparation of 4-[2-(methyl-2-pyridinylamino) ethoxy] benzaldehyde, an intermediate for the preparation of rosiglitazone | Cadila Pharmaceuticals Limited (IN) | 2008-04-02 | — | — | EP | disclosed |
| EP-1902061-A1 | PROCESS FOR MAKING DIPHOSPHINE-RUTHENIUM-DIAMINE COMPLEXES | Dow Gloval Technologies Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007005550-A1 | PROCESS FOR MAKING DIPHOSPHINE-RUTHENIUM-DIAMINE COMPLEXES | DOW GLOBAL TECHNOLOGIES INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20060173182-A1 | Process of preparing imatinib and imatinib prepared thereby | CIPLA LIMITED (IN) | 2006-08-03 | — | — | US | disclosed |
| EP-1599462-A2 | PROCESS OF PREPARING IMATINIB | Cipla Ltd. (IN) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004074502-A2 | A PROCESS OF PREPARING IMATINIB | CIPLA LTD (IN) | 2004-09-02 | — | — | WO | disclosed |
| EP-0559363-A1 | 3-Phenyl-5-pyridyl triazoles and their use as insecticides | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1993-09-08 | — | — | EP | disclosed |
| US-4028278-A | Cycloaliphatic unsaturated ketones as fragrance modifying agents | FIRMENICH S.A. (CH) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173182-A1 | Process of preparing imatinib and imatinib prepared thereby | ABL1, ABL2, MET | CA2 903/4885TTR 1182/4885TDP1 3626/4885 |
| US-20100179323-A1 | PROCESS FOR MAKING DIPHOSPINE-RUTHENIUM-DIAMINE COMPLEXES | DPY30, POP1, PPIP5K2 | CA2 3954/4885TTR 1967/4885TDP1 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.